An Update on the Clinical Management of Cutaneous Molluscum Contagiosum

Harrison P. Nguyen, BA; Stephen K. Tyring, MD, PhD, MBA

Disclosures

Skin Therapy Letter. 2014;19(2) 

In This Article

Conclusion

Currently, there is no FDA approved therapy for molluscum contagiosum and there is no widely accepted standard of care. Many pediatricians favor spontaneous resolution over aggressive therapy. However, research should continue to be conducted in hope of finding an answer to this common, pediatric infectious disease. In addition, sexually transmitted molluscum should be treated not only for the benefit of the patient, but also to prevent spread to sexual partners. Most importantly, standardized therapy should be developed for immunocompromised patients, who may suffer both physically and psychologically from widespread molluscum, especially on the face and genitalia. Future studies should investigate outcome measures such as recurrence and transmission rates, disease-related quality of life, and scarring. A standardized outcome measure for each treatment would facilitate comparative assessment.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....